Clinical Trials Directory

Trials / Unknown

UnknownNCT00697021

Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance

Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance in The Patients Treated With Primary PCI for STEMI

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Assaf-Harofeh Medical Center · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

TEG is an established technique to assess the quality of clot formation' used mainly in surgery and obstetrics to determine possible bleeding diathesis. Recently it became to be used in cardiology, where it can be a valuable tool to assess a response to antiplatelet therapy and its association with the outcome. However, there is a few data about use of TEG in STEMI patients undergoing PCI. Our study is designed to assess by TEG the platelet's response to clopidogrel treatment during acute STEMI in patients undergoing primary PCI and the correlation of this response with the long term outcome, and ability to dose adjustment according to a specific measurement by TEG in order to prevent future MACE.

Detailed description

TEG system may provide the capabilities needed to deliver personalized therapy, first, because it can identify patients at risk of ischemic event based on hemostatic influences, particularly platelet aggregation and platelet reactivity. Secondly, because treating those patients who exhibit high platelet reactivity -- an indication that they are not reaching a therapeutic level -- with appropriate drugs and doses is expected to improve outcomes. In this study that would be increased clopidogrel maintenance dosing (150 mg) or aspirin maintenance dosing to 200mg in an attempt to lower platelet reactivity below the 50th%ile, which we expect to also reduce their ischemic risk during the follow up period.

Conditions

Interventions

TypeNameDescription
DRUGAspirin (200mg) and/or Plavix (150mg) dosage according to TEGNon- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
DRUGAspirin 100mg and Plavix 75mgResponders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix

Timeline

Start date
2008-06-01
Primary completion
2009-06-01
Completion
2009-10-01
First posted
2008-06-13
Last updated
2008-06-13

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT00697021. Inclusion in this directory is not an endorsement.